Publications by authors named "R W Y Ko"
The patient was a 52-year-old male, who, after experiencing lower back pain, underwent further investigation and was diagnosed with hepatocellular carcinoma with sacral metastasis. The hepatocellular carcinoma was a 9 cm tumor with a risk of rupture. Liver resection was performed, and lenvatinib was initiated at a dose of 4 mg/day postoperatively.
View Article and Find Full Text PDFArticle Synopsis
- About 62.3% of critically ill patients admitted for sepsis developed acute kidney injury (SA-AKI) during their hospital stay.
- The study found that severe SA-AKI significantly increased the risk of in-hospital mortality among these patients.
- Proper hydration and fluid resuscitation within the first hour of treatment were linked to lower mortality rates in patients with severe SA-AKI.
Article Synopsis
- Low-frequency noise (LFN) in semiconductor devices is critical for understanding their performance and material defects.
- Research on ambipolar transistors and their LFN characteristics has been limited, prompting this investigation into MoTe transistors.
- The study finds that CYTOP-induced p-type doping alters carrier transport, reducing n-type noise and contact resistance effects while affecting LFN differently between n-type and p-type modes.
Flexible and navigable suction ureteral access sheath (FANS) is a potential game changer in flexible ureteroscopy (FURS). The influence of sheath size on outcomes needs research. The primary aim was to analyze 30-day single stage stone free status (SFS), zero fragment rate (ZFR) and complications when using 10/12Fr sheaths vis a vis other sheath sizes.
View Article and Find Full Text PDFEfficacy of subsequent treatment for unresectable locally-advanced non-small cell lung cancer after relapse of concurrent chemoradiotherapy with durvalumab consolidation therapy: A single-center retrospective study.
Cancer Treat Res Commun
December 2024
Objectives: The current standard treatment for locally advanced non-small cell lung cancer (LA-NSCLC) is concurrent chemoradiation therapy (CCRT) followed by durvalumab consolidation therapy. Although the trial revealed the survival benefit of adding an immune checkpoint inhibitor (ICI) to the population, the optimal treatment strategy and efficacy of subsequent treatment after relapse remain unclear.
Materials And Methods: We retrospectively collected data from patients with unresectable LA-NSCLC who completed platinum-based CCRT as first-line treatment.